Scarica l'app Stockscreener
60.84
4.16%
-3.405
Cg Oncology Inc Borsa (CGON) Ultime notizie
CG Oncology, Inc. Announces Chief Commercial Officer Search and Executive Changes in May 2026 8-K Filing - Minichart
CG Oncology (CGON) President & COO to depart as Arthur Kuan named President - Stock Titan
CGON Stock Chart | CG ONCOLOGY INC (NASDAQ:CGON) - ChartMill
CG Oncology Touts Bladder Cancer Data, Q4 Filing Plans at RBC Conference - MarketBeat
CGON: Cretostimogene advances toward broad NMIBC use with strong data, scalable manufacturing, and launch prep - TradingView
TimesSquare Capital Management LLC Decreases Stock Holdings in CG Oncology, Inc. $CGON - MarketBeat
Wolfe Research initiates coverage of CG Oncology (CGON) with peer perform recommendation - MSN
CG Oncology stock initiated at Peerperform by Wolfe Research - Investing.com Nigeria
Public immunotherapy drugmaker, Lyda Hill's investment firm grow at Pegasus Park - The Business Journals
CG Oncology Initiated at Peer Perform by Wolfe Research - Moomoo
CGON Initiated Coverage by Wolfe Research -- Rating: Peer Perfor - GuruFocus
SUO-CTC and CG Oncology Announce Award Recipients of the Second Annual Non-Muscle Invasive Bladder Cancer (NMIBC) Research Fellowship Award - The Manila Times
Bladder cancer grants back AI biomarker, price transparency research - Stock Titan
CG Oncology stock initiated at Peerperform by Wolfe Research By Investing.com - Investing.com South Africa
Wolfe Research Initiates CG Oncology(CGON.US) With Hold Rating - Moomoo
CGON Reiterated by HC Wainwright & Co. -- Price Target Maintained at $100 - GuruFocus
CG Oncology, Inc. engages with urology leaders at AUA26 to advance patient care connections - Traders Union
UBS reiterates Buy on CG Oncology stock, cites combo trial data - Investing.com Canada
CG Oncology Price Target Maintained With a $100.00/Share by HC Wainwright & Co. - Moomoo
Wedbush Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $80 - Moomoo
H.C. Wainwright Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $100 - Moomoo
Assessing CG Oncology (CGON) Valuation After Strong Phase 2 CORE 008 Cohort CX Trial Data - Sahm
Assessing CG Oncology (CGON) Valuation After Positive Phase 2 CORE-008 Bladder Cancer Data - Yahoo Finance
LifeSci Capital Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $108 - Moomoo
Why CG Oncology Stock Is Sliding Despite Good News - TipRanks
CG Oncology Reports 'Encouraging' Data From Study of Intravesical Combination Therapy to Treat Bladder Cancer - Moomoo
CG Oncology reports positive phase 2 bladder cancer trial data - Investing.com UK
T. Rowe Price (CGON) reports 6.72M shares, 8.0% stake disclosed - Stock Titan
CG Oncology reports positive phase 2 bladder cancer trial data By Investing.com - Investing.com South Africa
CG Oncology Reports Positive First Results from CORE‑008 Cohort CX Phase 2 Trial Evaluating Intravesical Combination Therapy in High-Risk BCG-Exposed and BCG-Unresponsive Patients - The Manila Times
RTW Investments Takes Shared 8.3% Stake in CG Oncology (CGON) - Stock Titan
Bladder cancer trial sees up to 92.3% response with new drug combo - Stock Titan
CG Oncology BLA Filing on Track as Key Bladder Cancer Data Nears - MarketBeat
Truist raises CG Oncology stock price target to $82 on NMIBC data - Investing.com
Truist Financial Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $82 - Moomoo
CG Oncology, Inc. (NASDAQ:CGON) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
CG Oncology stock hits all-time high at 73.61 USD - Investing.com India
CG Oncology stock hits all-time high at 73.61 USD By Investing.com - Investing.com Nigeria
CG Oncology (NASDAQ:CGON) Sets New 12-Month HighStill a Buy? - MarketBeat
BofA Securities Maintains CG Oncology(CGON.US) With Buy Rating, Maintains Target Price $83 - Moomoo
Number of shareholders of CG Oncology, Inc. – NASDAQ:CGON - TradingView
Q2 Earnings Estimate for CG Oncology Issued By HC Wainwright - MarketBeat
Bank of America Securities Reaffirms Their Buy Rating on Aktis Oncology, Inc. (AKTS) - The Globe and Mail
2.25%
0.46%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):